Statement of Principles concerning Parkinson disease and Secondary Parkinsonism (Reasonable Hypothesis) (No. 87 of 2025)

The Statement rests on three core concepts: definition of the disease entities, a catalogue of qualifying factors, and the linkage requirement to relevant service.

Definitions

• Parkinson disease is defined as a neurodegenerative disease involving progressive failure of dopaminergic transmission in the nigrostriatal system, characterised clinically (bradykinesia, rigidity, resting tremor, postural instability), pathologically (loss of dopaminergic neurons in substantia nigra pars compacta and alpha‑synuclein Lewy bodies) and with explicit exclusions that remove Secondary Parkinsonism and Parkinson Plus diseases from this definition (section 7(2)(a)-(c)).
• Secondary Parkinsonism is defined as an acquired movement disorder caused by exogenous factors that interfere with dopaminergic transmission in the nigrostriatal system, with a clinical characterisation identical to Parkinson disease but a separate exclusion list (section 7(2)(d)-(f)).
• Death from Parkinson disease and Secondary Parkinsonism includes deaths where the terminal event or condition was contributed to by the person’s Parkinson disease or Secondary Parkinsonism (section 7(3); Schedule 1 definition of terminal event).

Qualifying factors

• Section 9 sets out discrete, alternative factors. The RMA frames these as minimum requirements, such that at least one listed factor must exist before a reasonable hypothesis can be raised. Examples include: moderate to severe traumatic brain injury or concussion with specified time windows; cumulative exposure thresholds for trichloroethylene (2,000 hours) and certain pesticides (1,000 hours) with defined lookback periods; metabolic or medical states such as diabetes mellitus or disorders of calcium metabolism; specific toxic intoxications (manganese, cyanide, methanol/ethylene glycol) with biochemical evidence requirements; prescribed durations of medication use, including an extensive specified list of medications; lifestyle factors such as consuming at least 1 litre of cow’s milk daily for set periods; and functional incapacity measured in METs (inability to undertake physical activity greater than 3 METs for defined durations) (section 9 and Schedule 1 definitions).
• The Statement differentiates onset versus clinical worsening windows. Some factors are relevant only when they precede initial clinical onset by specified lead times (e.g. 15 years for moderate to severe TBI, 20 years for trichloroethylene exposure), while others can be relevant to clinical worsening within shorter windows (e.g. within 1 year for TBI before clinical worsening). The instrument specifies both types (section 9).

Linkage to service

• The instrument requires that any factor must be related to the person’s relevant service. “Relevant service” is defined to include the categories of operational, peacekeeping, hazardous and British nuclear test defence service under the VEA and warlike and non‑warlike service under the MRCA (Schedule 1). The instrument also limits the application of the “clinical worsening” aspect to material contribution or aggravation where the disease was suffered or contracted before or during, but did not arise out of, relevant service (section 10).

Interoperation with other Statements

• If a factor refers to an injury or disease covered by another Statement determined under subsection 196B(2) of the VEA, then the factors in that other Statement apply (section 11). The instrument therefore sits within a network of Statements used for different conditions and injuries.

Operational thresholds and evidentiary items

• Many qualifying factors require cumulative exposure thresholds expressed in hours or durations of medication, dates relative to clinical onset/worsening, or objective evidence such as neuroimaging findings of white matter lesions, haemorrhage or infarction (section 9 and Schedule 1).

The instrument is primarily technical and evidentiary. It operationalises the RMA’s view about which medical and exposure factors create a reasonable hypothesis of causation between service and Parkinson disease or Secondary Parkinsonism. It shapes which factual pathways will enable an administrative decision‑maker to advance a claim to merits consideration under the statutory tests in the VEA and MRCA.

Claimants and beneficiaries

• The most immediate group affected are veterans, members of Peacekeeping Forces and members of the Forces covered under the MRCA who either have Parkinson disease or Secondary Parkinsonism, or whose death involved those conditions. The instrument applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (section 5). Those statutory sections concern the acceptance of conditions as service related for entitlement purposes; the Statement supplies the medical thresholds that decision‑makers use in applying those statutory provisions.

Decision‑makers and agencies

• Decision‑making bodies that determine entitlements under the VEA and MRCA will use this Statement as a medical benchmark. The RMA’s Statements are applied by the Department of Veterans’ Affairs and related decision‑making tribunals and commissions. While the instrument itself does not instruct those bodies’ procedural practices, it imposes an evidentiary framework that they must incorporate when assessing whether a reasonable hypothesis exists.

Medical practitioners and expert witnesses

• Clinicians, occupational medicine specialists, neurologists, toxicologists, and medico‑legal experts who prepare opinions for claimants or agencies will need to align their assessments to the definitions, thresholds and temporal windows set out in the Statement. For example, assessments must address whether a claimant had cumulative exposure meeting the 1,000 or 2,000 hour thresholds, whether neuroimaging shows the lesions required for certain vascular disorders, or whether biochemical evidence of intoxication exists for methanol or ethylene glycol (section 9 and Schedule 1).

Employers, former employers and record keepers

• Where occupational exposure information is required (for example, cumulative exposure to trichloroethylene, pesticides, manganese or carbon disulphide), employers and occupational health record‑keepers will be relevant sources of evidence. The instrument’s reliance on cumulative hours or specific employment contexts means that accurate occupational records can materially affect claim outcomes.

Service record custodians and unit commanders

• Establishing that a qualifying factor is related to “relevant service” requires linking the exposure or event to service records. Unit deployment logs, occupational role descriptions, and hazard reports retained by Defence and other agencies will be needed to establish the service nexus.

Insurers and compensation administrators

• Although the Statement applies in the veterans’ entitlements framework, private insurers and compensation bodies may be indirectly affected where medical expert evidence produced for these claims is influenced by the thresholds and definitions in the Statement.

Populations with concentrated exposure

• The instrument’s chosen factors and thresholds make specific occupational and environmental exposures salient. Veterans who worked in engineering trades, maintenance, logistics, aviation, ordnance, or in roles involving pesticides or solvents may be over‑represented among those able to meet the cumulative exposure thresholds. Those who used beta‑blockers, certain antipsychotics, or other specified medications within the timeframes will likewise be affected for purposes of Secondary Parkinsonism.

Researchers and policy analysts

• The Statement codifies the RMA’s view of the medical evidence. Researchers who analyse patterns of accepted claims, or the fiscal impact of entitlements, will use the Statement as the medical standard that underpins acceptance rates and the allocation of resources within the veterans’ compensation system.

Who does not automatically benefit

• Meeting a listed factor is described as a minimum before a reasonable hypothesis can be raised; the Statement does not automatically create entitlement. Individuals whose conditions fall within the excluded categories in the definitions (for example, Parkinson Plus diseases or dementia pugilistica as listed in section 7(2)) are outside the Statement’s scope for Parkinson disease as defined. The Statement also does not itself change non‑medical eligibility criteria in the VEA or MRCA, such as the requirement that the factor be related to relevant service (section 10).

In short, this Statement affects claimants, medical advisers and decision‑makers by specifying the medical and exposure thresholds which will be used to establish a reasonable hypothesis of service connection for Parkinson disease and Secondary Parkinsonism. Those with the exposures, illnesses or medication histories enumerated in section 9 will generally find the Statement material to their claims, while those without such evidence must rely on other medical pathways or legal arguments outside this Statement.

Rights created or enabled

• The Statement enables claimants to raise a “reasonable hypothesis” that Parkinson disease or Secondary Parkinsonism is related to relevant service if at least one of the listed factors in section 9 exists. The RMA frames these factors as the minimum evidence needed for a reasonable hypothesis. Practically, where a claimant provides evidence satisfying a listed factor, decision‑makers are empowered to find a plausible service link sufficient to proceed to merits consideration under the VEA and MRCA statutory tests. The Statement therefore creates a predictable medical evidentiary pathway for claimants.

Duties on decision‑makers (administrative application)

• The instrument does not contain express procedural directions requiring a particular decision from decision‑makers. However, its functional effect is to supply the medical thresholds and definitions that decision‑makers must apply when determining whether a reasonable hypothesis exists. The decision‑maker must examine whether the claimant has produced evidence of at least one of the section 9 factors and whether that factor is related to relevant service (section 10). Also, where a factor refers to an injury or disease covered by another Statement, the decision‑maker must apply the factors in that other Statement as in force (section 11). The duty is therefore evidentiary and interpretative: apply the Statement’s factor list and Schedule 1 definitions when assessing causation.

Duties on claimants and medical advisers

• Claimants and their medical advisers must put forward evidence that corresponds with the instrument’s thresholds. For example, if relying on cumulative exposure to trichloroethylene, evidence must aim to demonstrate a cumulative period of at least 2,000 hours and relate that exposure to service periods specified in the Statement (section 9). If relying on neuroimaging criteria for cerebral vessel disease, the relevant imaging reports must be presented as required by the Statement (section 9 and Schedule 1). Claimants have the right to request that decision‑makers consider these factors as the benchmark for a reasonable hypothesis.

Interaction with other Statements and legal rights

• Where a factor in section 9 refers to another Statement of Principles, the claimant can rely on that other Statement’s factors in place of the simple reference. This cross‑reference creates a right to have linked conditions assessed under the applicable Statement as it stands at the time of adjudication (section 11).

Limitations on rights and duties

• The Statement establishes only a threshold for a reasonable hypothesis. It does not itself determine entitlement; statutory entitlement requires further satisfaction of VEA or MRCA tests. The instrument does not set out burden of proof rules, discharge standards, or appeal rights,these are governed by the underlying Acts and administrative law. The instrument also specifies exclusions in the definitions which remove certain diseases or presentations from the Statement’s scope (section 7(2)).

Evidence specificity and obligations

• Several factors require objective evidence: biochemical confirmation of intoxication, neuroimaging showing white matter lesions or infarction, documentation of durations of medication therapy, or clinical records showing timing of onset and worsening. The claimant’s duty, operationally, is to supply evidence that maps to these specified forms, because the Statement sets those forms as the minimum for raising a reasonable hypothesis (section 9 and Schedule 1).

Administrative discretion and how the Statement constrains it

• The RMA’s Statement narrows administrative discretion by prescribing which medical and exposure attributes are sufficient to raise a reasonable hypothesis, and by giving precise timing and exposure thresholds. Decision‑makers retain discretion beyond the threshold,meeting a factor allows but does not compel acceptance,however, absence of the listed factors is likely to make a reasonable hypothesis harder to establish under the RMA’s articulated view (section 9 and section 8).

In sum, the key rights are claimants’ ability to raise a reasonable hypothesis by relying on the enumerated factors. The key duties fall on claimants to provide evidence matching those factors and on decision‑makers to apply the Statement’s definitions and cross‑references in assessing whether a reasonable hypothesis exists. The Statement provides a structured evidentiary ceiling and floor for medical causation inquiries in the veterans’ entitlements framework, but it does not itself determine entitlement or prescribe tribunal procedure.

No criminal penalties or civil fines

• The instrument contains no penal provisions, criminal sanctions or civil fines. It is a medical Statement made under subsection 196B(2) of the VEA and functions as a standard for administrative decision‑making, not as a regulatory instrument that imposes penalties (sections 3 and 8).

Enforcement mechanism: administrative decisions on entitlements

• Enforcement in practice occurs within the administrative framework of the VEA and MRCA. The Statement supplies the evidentiary thresholds decision‑makers use to determine whether a reasonable hypothesis exists that a condition is service related. Acceptance or rejection of a claim under the VEA or MRCA, and consequent benefits payments or denial, are the operational enforcement mechanisms that follow from applying the Statement. The instrument itself does not specify procedures for notification, appeals, review, or compliance monitoring; those remain within the statutory frameworks and administrative practices of the Department of Veterans’ Affairs and review bodies.

Admissibility and evidentiary effect

• The Statement gives the RMA’s view that if at least one of the enumerated factors exists, a reasonable hypothesis may be raised (section 9). That view has legal and administrative significance: decision‑makers are expected to consider the Statement as authoritative medical guidance when adjudicating claims. The weight given to the Statement in judicial review or tribunal proceedings is determined by the underlying statutory context and judicial precedent. The instrument does not itself create enforceable rights against non‑government actors or bind courts, but it will be a relevant and frequently decisive administrative document in merits decisions.

No express compliance oversight or reporting obligations

• The Statement does not create reporting obligations for service agencies or employers, nor does it create requirements for data collection or disclosure. It instead sets evidentiary expectations for claimants and decision‑makers. Practical enforcement of these expectations occurs through the claim process: evidence produced, and administrative findings made, on the basis of the Statement will determine whether statutory entitlements are paid.

Interaction with other administrative remedies

• Where a claimant disagrees with a decision applying the Statement, remedies such as internal review, merits review by the Veterans’ Review Board or Administrative Appeals Tribunal (as applicable under the VEA and MRCA frameworks), and judicial review remain available under the relevant Acts. This Statement will be a primary piece of medical evidence that reviewers examine; the Statement does not specify appeal routes or timeframes.

Potential administrative consequences of inaccurate evidence

• The instrument does not set penalties for false statements or fabrication of evidence. However, existing statutory and administrative safeguards and offences in the VEA and MRCA frameworks concerning fraudulent claims or misleading conduct remain applicable. The Statement does not alter those regimes.

In short, the instrument uses administrative adjudication as the enforcement mechanism. It does not itself impose criminal or civil penalties, nor does it create additional reporting or compliance obligations beyond the evidentiary expectations it establishes for claims under the VEA and MRCA.

Statutory basis and connection to VEA and MRCA

• The Statement is made under subsection 196B(2) of the VEA (section 3). It is expressly intended to apply to claims to which section 120A of the VEA or section 338 of the MRCA applies (section 5). Those statutory provisions govern how entitlements are determined for conditions that are alleged to be related to service. The Statement therefore operates as a medically grounded instrument that decision‑makers must use when applying the statutory causation tests in the VEA and MRCA.

Cross‑references to other RMA Statements

• Section 11 states that if a factor referred to in section 9 applies and that factor refers to an injury or disease covered by another Statement determined under subsection 196B(2) of the VEA, then the factors in that other Statement apply in accordance with its terms as in force from time to time. This creates an integrated network of Statements where one Statement defers to another for particular medical conditions or injuries. It means that, procedurally, decision‑makers cannot treat the factors in isolation if they relate to a disease covered by another Statement; they must apply that other Statement’s factors.

Interaction with evidentiary rules and administrative law

• The Statement sets the medical content of what will be considered sufficient to raise a reasonable hypothesis. The manner in which evidence is produced, tested, and weighed remains governed by administrative law principles under the VEA and MRCA frameworks, and by general principles of procedural fairness, admissibility and the relevant review mechanisms. The Statement does not override statutory appeals or judicial review rights.

Overlap with occupational health and safety law, workers’ compensation and private insurers

• The Statement addresses causation for veterans’ entitlements. It does not amend or displace state and territory occupational health and safety laws, workers’ compensation schemes, or private insurance entitlements. However, medico‑legal evidence prepared in accordance with the Statement (exposure histories, toxicology, imaging) will be relevant across compensation jurisdictions. There is no cross‑binding effect requiring other schemes to adopt the RMA’s thresholds; those other schemes apply their own standards. The instrument does, however, create a de facto national medical standard in the veterans’ entitlements context which may inform expert evidence elsewhere.

Medical regulation and professional duties

• The Statement interfaces with professional clinical obligations where treating clinicians and medico‑legal experts must document history and objective evidence in ways that correspond with the Statement’s thresholds. The Statement does not create new clinical standards or change regulatory obligations on health professionals; it does influence the content of medico‑legal reports used in administrative adjudication.

Human rights and discrimination law

• The instrument is silent on human rights or discrimination law. It neither creates nor removes statutory protections in those domains. That said, administrative decisions influenced by the Statement will remain subject to general legal constraints, including obligations not to discriminate unlawfully in decision‑making. The Statement itself is a medical evidentiary document and does not explicitly address human rights considerations.

Relevance to criminal law

• The Statement does not interact with criminal law. Events such as traumatic brain injury or exposure leading to intoxication may also be relevant to criminal liability in particular factual situations, but the Statement does not make findings about criminal responsibility or offences.

In summary, the principal legal interaction is with the statutory schemes that determine veterans’ entitlements (VEA and MRCA). The Statement is an administrative, medical standard that decision‑makers must apply when testing whether a reasonable hypothesis exists that Parkinson disease or Secondary Parkinsonism is related to relevant service. It cross‑references and defers to other RMA Statements where applicable, but it does not itself create or modify rights or duties in other legal domains such as workers’ compensation or criminal law.

Immediate amendment action recorded in the instrument

• The Statement expressly repeals an earlier Statement on the same subject: “The Statement of Principles concerning Parkinson’s disease and secondary parkinsonism (Reasonable Hypothesis) (No. 55 of 2016) (Federal Register of Legislation No. F2016L00560) made under subsection 196B(2) of the VEA is repealed” (section 4). The instrument therefore replaces the 2016 Statement with the 2025 Statement. It is dated 24 October 2025 and provided to commence on 24 November 2025 (sections marked for Name, Commencement and the dated signature block).

No further amendments listed

• The instrument does not record any other amendments, transitional provisions or savings clauses. It does not specify whether decisions made under the repealed 2016 Statement remain valid, or how in‑flight claims that were assessed under the former Statement should be handled. The only temporal detail supplied is the commencement date and the repeal of the prior Statement (sections 2 and 4).

Versioning and “as in force from time to time”

• Section 11’s cross‑reference to other Statements says the factors in those Statements apply “as in force from time to time”. That language implies that the RMA updates Statements and later versions will govern cross‑referenced factors. The present instrument does not contain a schedule of prior amendments to itself; it is presented as the current Statement that replaces the 2016 version.

What is not in the instrument

• The instrument does not include comparative notes explaining which parts differ from the 2016 Statement or why particular changes were made. The RMA’s explanatory memorandum or reasons (if any) are not included in the text provided. The Statement itself does not list consultation history, stakeholder submissions, or the specific scientific evidence the RMA relied on beyond the general statement in section 8 that there is sound medical‑scientific evidence.

Practical implication of repeal

• By repealing the 2016 Statement, the RMA has created a new baseline for assessing claims from the commencement date. All adjudications after commencement must reference the 2025 Statement. The instrument does not specify whether claims lodged before commencement but decided after it will be assessed under the older or newer Statement; that procedural question will be determined by applying the VEA and MRCA decision‑making rules and administrative transitional practice.

Recordkeeping and future amendment

• The Statement appears as a stand‑alone instrument in the Federal Register of Legislation. Future amendments to the RMA’s Statements will be reflected in later instruments and will govern cross‑referenced factors “as in force from time to time” (section 11). Practitioners should monitor the RMA’s releases for updated or replacement Statements and any explanatory material setting out the evidence base for changes.

In short, this instrument constitutes a complete repeal and replacement of the 2016 Statement for Parkinson disease and Secondary Parkinsonism. It does not itself include an amendment record beyond that repeal, nor does it include explanatory material within the instrument text provided.

Instrument contains no litigation references

• The Statement itself contains no citations of judicial determinations, tribunal decisions, or references to litigation. It does not record any cases or legal challenges to either the 2016 Statement or earlier instruments. The text supplied makes no mention of litigation history or judicial consideration.

Implication for legal practice

• Because the instrument does not cite cases, practitioners cannot rely on litigation examples within the Statement to predict how courts or tribunals will treat it. The Statement will nonetheless be central evidence in administrative decision‑making and will likely be considered in merits review and judicial review proceedings where causation issues arise under the VEA and MRCA. Any litigation over the application of the Statement would proceed under the usual review routes in the relevant statutes, but the instrument itself does not record such matters.

What to expect in contested matters

• Where the Statement is pivotal to an entitlement decision, contested matters could raise issues such as the interpretation of timing windows (onset versus worsening), how to calculate cumulative exposure hours, what constitutes adequate biochemical evidence of intoxication, and how to apply cross‑references to other Statements. These are issues that tribunals or courts could be asked to resolve in the context of appeals from administrative decisions, but the instrument does not supply authority on those points.

No noted precedent within the instrument

• The absence of any litigation history in the instrument means it is a pure administrative medical standard rather than a document that summarises or endorses particular tribunal or judicial lines of reasoning. Practitioners should therefore be prepared to argue statutory and evidentiary points drawing on external jurisprudence where applicable, but must do so without direct precedent citations from the Statement itself.

Monitoring for future litigation

• Given the Statement’s detailed thresholds and the potential evidentiary difficulty of establishing cumulative hours or biochemical evidence decades after exposure, contested decisions and litigation over proof and interpretation are plausible. Practitioners should monitor tribunal and court decisions that deal with application of RMA Statements generally and this Statement in particular as those decisions will flesh out how the administrative standard is interpreted in practice.

In summary, the Statement contains no litigation history within its text. Any litigation arising from disputes about its application will be found in external records of tribunals and courts, not within the instrument itself.

Precision of timing and cumulative thresholds

• The Statement uses precise numerical thresholds and time windows. For example, trichloroethylene exposure requires a cumulative period of at least 2,000 hours and either at least 20 years before clinical onset or within the 20 years before clinical worsening (section 9). Pesticide exposures require 1,000 cumulative hours with varying lookback windows. Carbon disulphide has a 500 hour threshold within 10 years. These are not approximate indicators: they are explicit minimums that claimants must evidence to raise a reasonable hypothesis. Failure to demonstrate the exact or greater cumulative hours and timing will make it difficult to rely on the factor.

Onset versus clinical worsening

• The instrument draws a sharp distinction between clinical onset and clinical worsening. Many factors are relevant only to clinical worsening in relatively short windows (3 months, 1 year, 10 years) while others require long pre‑onset windows (15 or 20 years). Practitioners must carefully document the date of clinical onset and the date of any clinical worsening, because the same exposure may count for one but not the other. The Statement also restricts the clinical worsening application to conditions that were “suffered or contracted before or during (but did not arise out of) the person’s relevant service” (section 10(2)). That phrasing is a specific gateway and may exclude certain aggravations if the illness first arose out of service.

Cumulative exposure measurement challenges

• The instrument requires cumulative hours for exposures (for example, 1,000 or 2,000 hours). Practically, proving cumulative hours decades later can be very difficult. The Statement does not specify accepted methods for conversion from job duties to hours, nor does it permit presumptions. Evidence may need to come from employment records, shift rosters, occupational exposure assessments or witness statements. The lack of a prescribed method for calculating cumulative exposure is a practical gap that increases evidentiary burden for claimants.

Objective evidence requirements

• Several factors require objective biochemical, haematological or neuroimaging evidence. For example, methanol or ethylene glycol exposure must be accompanied by clinical, haematological or biochemical evidence of intoxication within a 3 month window before worsening (section 9). Cerebral vessel disease requires neuroimaging findings of white matter lesions, haemorrhage or infarction at the time of clinical worsening. If objective evidence is absent, a claimant may not meet the minimum despite having a plausible exposure history.

Wide and specific medication list

• The Schedule lists a very large assortment of “specified list of medications” which, if taken for at least one week within 3 months before clinical worsening, are factors. The list spans commonly used drugs and rare agents. Practitioners must check dispensary, PBS, GP and specialist records meticulously because even short courses can be relevant. There are separate rules for medications that cause development of Secondary Parkinsonism where cessation within 12 months is relevant, and for medications associated with clinical worsening where cessation within 3 months is relevant, each with their own minimum treatment durations (section 9).

Definitions that adjust interpretations

• Critical definitions in Schedule 1 can change how a factor is applied. For instance, “regular smoking habit” requires at least 5 pack‑years within a continuous 5 year period. A claimant who smoked intermittently or whose pack‑year calculation falls short will not meet the “regular smoking habit” definition and cannot rely on the “not smoked for at least the 5 years before onset” factor. The “one pack‑year” definition and conversion notes are also prescriptive and affect how smoking history is quantified.

Exclusions in disease definitions

• Parkinson disease’s definition expressly excludes Secondary Parkinsonism, Parkinsonism in other primary neurodegenerative diseases, and Parkinson Plus diseases. For claimants whose diagnosis is ambiguous between Parkinson disease and a Parkinson Plus condition, the Statement’s exclusions will be material. The instrument requires a clinical characterisation consistent with Parkinson disease (bradykinesia etc.) and, for pathological confirmation, Lewy bodies or Lewy neurites. Where diagnostic certainty is lacking, claim outcomes may be affected.

“Related to relevant service” gateway

• Section 10 requires the existence of a listed factor be related to the relevant service rendered by the person. The Statement does not define how the service nexus is to be established beyond referring to “relevant service” categories in Schedule 1. Establishing that the exposure or injury occurred in service may require corroborative evidence from service records, logs, occupational allocations or other documentary or testimonial sources. Failure to link the factor to service will prevent the Statement from assisting a claimant.

Cross‑references to other Statements

• Where a factor refers to an injury or disease covered by another Statement, the other Statement’s factors apply “as in force from time to time” (section 11). This means that a claimant may end up being assessed against a different or updated set of factors, and that practitioners must check the current text of any cross‑referenced Statements.

“Clinical or biochemical evidence” ambiguities

• The instrument repeatedly uses phrasing such as “having clinical, haematological or biochemical evidence of” an intoxication or condition. It does not, however, specify cut‑off values, test types or interpretive standards. This leaves open the possibility of disputes over what constitutes adequate laboratory evidence for intoxication or what level of neuroimaging abnormality satisfies the requirement.

Burden of proof and administrative standards

• The instrument sets out the medical minima for a reasonable hypothesis, but it does not alter burdens of proof in the statutory schemes. Practitioners must be careful not to assume that satisfying a listed factor automatically satisfies other statutory elements or the ultimate onus in a contested case. The Statement is an enabling document, not a substitute for statutory proof burdens.

Potential for narrow interpretative readings

• Decision‑makers might adopt narrow readings of timing or exposure thresholds, treating the numerical thresholds as prerequisites rather than flexible guides. Given the instrument’s language that the factors “must as a minimum exist”, claimants should anticipate strict scrutiny on whether the factor is proven to the Statement’s specific terms.

Evidence preservation problems

• Many relevant exposures and medical events are historical. Records may be lost, destroyed or never created. Practitioners should attend early to preservation and collation of evidence; late reconstruction may be less persuasive and risk rejection under the instrument’s precise thresholds.

In sum, the principal “gotchas” are the instrument’s precise thresholds, timing windows, objective evidence requirements, technical definitions, cross‑references, and the need to connect the factor to relevant service. These features raise evidentiary and procedural challenges for claimants and require careful, technical preparation of medico‑legal material.

For claimants and representatives: evidence mapping and timing

• Identify the diagnosis and whether it falls within the Statement’s definitions (section 7(2)). Collect clinical documentation that records bradykinesia, rigidity, resting tremor and postural instability and any non‑motor symptoms. If pathological reports are available, collect neuropathology notes regarding dopaminergic neuron loss and alpha‑synuclein Lewy bodies; though pathology is often not available during life, clinical evidence can suffice to identify the disease entity as per the Statement’s clinical characterisation.
• Determine whether the claim concerns clinical onset or clinical worsening. The Statement applies different factors and time windows to each. Accurately record the dates of initial clinical onset and any documented clinical worsening in medical records, ideally with dates and clinician notes that specify changes in function or symptom severity (section 9).
• Map the claimed factor(s) to the precise requirements in section 9. For each factor relied on, list the precise threshold and time window (for example: trichloroethylene 2,000 cumulative hours, 20 years before onset; pesticide 1,000 cumulative hours, 5 years before onset for Parkinson disease; carbon disulphide 500 hours, within 10 years before worsening). Cross‑check the Schedule 1 definitions to ensure that the exposure is the exact substance named or falls within a named class (section 9 and Schedule 1).

Sources of evidence

• Service records: deploy logs, unit assignments, job descriptions, hazard reports, and any service medevac or incident reports that evidence exposure events or traumatic injuries. The Statement requires the factor be related to relevant service (section 10 and Schedule 1 definition of relevant service).
• Occupational records: rosters, employment histories, safety data sheets, material safety data sheets (MSDS), exposure registers, and industrial hygiene monitoring records that can be used to estimate cumulative exposure hours.
• Medical records: hospital discharge summaries, emergency department notes for traumatic brain injury or concussion, GP and specialist letters documenting dates of onset and worsening, neuroimaging reports (MRI or CT) where cerebral vessel disease is alleged, biochemical and haematological test results for intoxication claims, and records of dialysis or total parenteral nutrition where manganese toxicity is alleged (section 9 and Schedule 1).
• Pharmacy and dispensing records: scripts and PBS records to establish dates and durations for medications, especially where the specified list of medications or beta‑blocker use are relied on (Schedule 1 specified list; section 9 medication timing rules).
• Lifestyle and functional assessments: documentation of inability to undertake activities greater than 3 METs may be supported by occupational therapy assessments, exercise testing, specialist notes, or disability assessments that quantify physical capacity.
• Toxicology and laboratory testing: where intoxication is alleged, provide contemporaneous biochemical evidence or hospital test results evidencing methanol/ethylene glycol intoxication, cyanide intoxication, manganese levels, or cholinesterase inhibition for organophosphate exposure (sections 9 and Schedule 1).

Assembling medico‑legal opinion

• Request a specialist report that explicitly addresses the Statement. The medical opinion should:
  • State the diagnosis and map it to the Statement’s clinical characteristics.
  • Identify the specific factor(s) relied on and explain how the claimant’s documented history meets the precise thresholds and timing windows in section 9.
  • Address whether objective evidence (imaging, biochemical tests) meets the Statement’s requirements and explain any gaps.
  • Express whether, on balance, the clinician considers that a reasonable hypothesis is raised that the factor is related to service, and identify where cross‑referencing to other Statements arises (section 11).
• Ensure the expert addresses causation in the terms used by the instrument: “reasonable hypothesis”, relation to relevant service, and whether the condition was suffered before or during service but did not arise out of service if relying on clinical worsening (section 10).

Practical litigation and review preparation

• Where an adverse decision is likely, prepare for review by ensuring the expert report addresses the Statement in detail. If a factor refers to another Statement, obtain and include that other Statement’s current text and relevant medical evidence. Because the Statement is likely to be the pivotal medical benchmark in review proceedings, the expert report should mirror its language and thresholds.

Document preservation and contemporaneous evidence

• Because many thresholds require historical evidence, preserve contemporaneous records early. Seek service records releases, submit Freedom of Information requests to Defence if necessary, and obtain old occupational records promptly. Where contemporaneous data is unavailable, collect corroborative statements and secondary evidence that assist in reconstructing exposure hours or event chronology, and ensure the medical expert addresses any limitations.

Common evidentiary pitfalls to avoid

• Do not conflate “regular smoking habit” with lighter or non‑continuous smoking; apply the Schedule 1 definition of 5 pack‑years within a continuous 5 year period. Use the Schedule 1 “one pack‑year” conversion to calculate pack‑years accurately.
• When relying on medications, check both the specified list and the alternative medication timing rules. Some drugs create Secondary Parkinsonism which resolves within 12 months of cessation; others can cause transient worsening which resolves within 3 months. Provide dispensing records to prove duration and timing.
• For exposures stated in cumulative hours, document both the duration and the duty pattern that generated the hours. Generic assertions of “worked with solvents” without quantification are unlikely to meet the numerical thresholds.

For decision‑makers and medical assessors: applying the Statement

• Confirm the dates of clinical onset and clinical worsening from medical records.
• Check whether the claimant has produced evidence that maps to any of the enumerated factors in section 9. If a factor is found, verify that it is temporally related to the person’s relevant service (section 10).
• Where a factor refers to a condition governed by another Statement, apply that other Statement’s factors as they are in force (section 11).
• Require objective evidence where the Statement requires it (biochemistry, neuroimaging, documented intoxication).
• Document reasons referencing the Statement’s clauses. Where a factor is not accepted, specify which numerical or definitional requirement was not met.

For recorders and administrators: process adjustments

• Update claim intake forms and medico‑legal referral templates to reflect the Statement’s specific thresholds, timings and required evidence types. Create checklists for the common factors (trichloroethylene, pesticides, traumatic brain injury, medication histories, intoxication biomarkers, neuroimaging).
• Train staff in the onset/worsening distinction and in the Schedule 1 definitions that are frequently decisive.
• Coordinate with Defence and other record custodians to streamline access to service records that establish the service nexus.

Monitoring and future proofing

• Because section 11 cross‑references factors in other Statements “as in force from time to time”, build a process to check for updates to other RMA Statements that may affect linked factors. Maintain a centralised repository of current RMA Statements and update templates and expert instructions accordingly.

In short, compliance requires tailored, evidence‑led case preparation that precisely maps claimant history onto the Statement’s numerical and temporal thresholds. Practitioners should plan early to obtain service and occupational records, contemporaneous medical evidence and specialist reports that expressly address the Statement’s requirements.